# Cytara Biologics

> Cytara Biologics is developing Invelis™, a pH-gated lipid-protein vesicle platform that delivers therapeutics directly to the cytosol of solid tumour cells via direct membrane fusion, bypassing the endosomal escape bottleneck that limits conventional LNP and exosome platforms.

Cytara Biologics is a UK-incorporated biotechnology company, founded in 2025 and based in Cambridge, UK. Our scientific programme is conducted in collaboration with the University of Southampton. Initial focus is solid tumour oncology, with a manufacturing architecture (microfluidic mixing) designed for reproducible, clinically scalable production from the outset.

Because the live site is a JavaScript-rendered single-page app, the markdown files linked below contain the full readable content of each page for AI assistants and crawlers that do not execute JS.

## Pages

- [Homepage](https://www.cytarabio.com/index.md): Problem, Invelis™ platform overview, competitive landscape, partnership categories, investor and contact info.
- [About](https://www.cytarabio.com/about.md): Company recognition (Impulse Programme 2026, Maxwell Centre, University of Cambridge), platform summary, founding team, base.
- [Full site](https://www.cytarabio.com/llms-full.txt): Concatenated content of every public page in one file.

## Contact

- hello@cytarabio.com: General enquiries
- invest@cytarabio.com: Investor enquiries